Fundz
Free weekly newsletter

Get the free weekly contract digest

The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.

Weekly Digest

New new contracts, summarized for you

Straight to Inbox

No login, no app to check — it comes to you

Contract Trends

See who's moving and how much in your market

No credit card required Weekly contract digest

ImmunoPrecise Antibodies and a Global Biotechnology Leader Enter into a USD $8M-$10M Partnership for the Development of Novel Cancer Therapeutics

Mar 13, 2025•over 1 year ago

Contract Type

partnership

VictoriaBiotechnologyTherapeutics

Description

ImmunoPrecise Antibodies Ltd. has announced a strategic partnership with a leading biotechnology company to advance the discovery and development of Antibody-Drug Conjugates (ADCs) and bispecific antibodies for cancer treatment. The partnership, valued at an initial $8 million with potential to expand to $10 million, will focus on integrating AI-driven discovery capabilities to enhance therapeutic development over 18 to 24 months.

Company Information

Company

ImmunoPrecise Antibodies (Europe) B.V

Location

Victoria, British Columbia, Canada

About

ImmunoPrecise Antibodies (Europe) B.V. specializes in antibody discovery, engineering, and characterization services. It operates in Europe and has advanced capabilities for recombinant protein expression. The company is a carve-out from ImmunoPrecise Antibodies Ltd.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Predictive Intelligence
Strategic

ML-powered predictions for ImmunoPrecise Antibodies (Europe) B.V's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.